Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
Obstetrics & Gynecology Science
; : 285-289, 2019.
Article
in En
| WPRIM
| ID: wpr-760645
Responsible library:
WPRO
ABSTRACT
The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Ovarian Neoplasms
/
Peritoneal Cavity
/
Peritoneal Neoplasms
/
Recurrence
/
Carboplatin
/
Cisplatin
/
Paclitaxel
/
Topotecan
/
Drug Therapy
/
Infusions, Parenteral
Limits:
Humans
Language:
En
Journal:
Obstetrics & Gynecology Science
Year:
2019
Type:
Article